RE:Looks like PL’s strategy was on full display today at the CCBiofinder wrote: 1) Concentrate on 4050 in IPF and Alstrom indications, 2) push Ryplazim for plasminogen deficiency and “low hanging fruit” indications (burns, acute, etc.), 3) market IVIG, 4) then sell the company.
(hence the dropped lucrative DFU indication imo)
All a question of getting that 4050 global Pharma deal , after that , pressure will be off to execute the rest of the plan, then we sell the whole thing ...